Pfizer SEC filings, summarized
We read every Pfizer 8-K filing and insider trade the night it hits SEC EDGAR, and turn it into a two-minute plain-English summary.
Track PFE in your inbox
Add Pfizer to your watchlist — free, every morning.
Recent filings
Pfizer Chairman and CEO Albert Bourla buys $1.0 million in stock
Pfizer Chairman and CEO, and Director, Albert Bourla bought 38,000 shares of common stock on the open market at $26.34 per share, for an approximate total…
Pfizer director Ronald E. Blaylock buys $998,821 in stock
Pfizer director Ronald E. Blaylock purchased 39,231 common shares in an open-market transaction at $25.46 per share, for an approximate total of $998,821.…
Pfizer director Buckley Mortimer J buys $960,369 in stock
Pfizer director Buckley Mortimer J purchased 37,632 shares of common stock in an open-market transaction at $25.52 per share, for an approximate total value…
Pfizer Raises 2026 Revenue Outlook After Second-Quarter Sales Growth
Pfizer reported second-quarter 2026 revenue of $15.0 billion, up 3% year over year, with adjusted diluted EPS of $0.77 and a GAAP loss of $0.04 per share…
PFIZER INC filed an 8‑K on Feb 3, 2026 attaching a press release (Exhibit 99) reporting Pfizer’s Q4 2025…
PFIZER INC filed an 8‑K on Feb 3, 2026 attaching a press release (Exhibit 99) reporting Pfizer’s Q4 2025 financial results — see the release for revenues,…
Pfizer ($PFE) issued a press release on Feb 3, 2026 announcing fourth‑quarter 2025 financial results; the…
Pfizer ($PFE) issued a press release on Feb 3, 2026 announcing fourth‑quarter 2025 financial results; the press release is furnished as Exhibit 99 to the…